EOS Technology Investment Syndicate
VC Fund
EOS Technology Investment Syndicate is a VC fund focused on Biotechnology and Health Care. EOS Technology Investment Syndicate
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries EOS Technology Investment Syndicate invests in
Stages EOS Technology Investment Syndicate invests in
Countries EOS Technology Investment Syndicate invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Biotechnology 3 (50%)
- Health Care 1 (17%)
- Life Science 1 (17%)
- Therapeutics 1 (17%)
- 3D Technology 1 (17%)
Stage
- Seed 2 (33%)
- Series A 1 (17%)
- Funding Round 1 (17%)
- Venture - Series Unknown 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kevin Grainger
Chairman & Gatekeeper
|
Chairman & Gatekeeper | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ILC Therapeutics
|
ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis. | $3.3M / Venture - Series Unknown / Sep 11, 2024 | |
|
ILC Therapeutics
|
ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis. | $4.8M / Venture - Series Unknown / Sep 06, 2021 | |
Chromacity
|
Chromacity Lasers is a spin-out from Heriot-Watt University, one of the UK’s leading technical universities with a focus on photonics. Their founding team has over 40 years’ experience in ultrafast lasers and fiber lasers. They have developed wavelength tunable femtosecond lasers from the ultraviolet (400 nm) to the mid-infrared (> 6 µm) forindustrial and scientific applications in fluorescence microscopy, gas spectroscopy, laser material processing and semiconductor engineering.Robust, patent-pending femtosecond fiber-laser technology underpins every product, delivering reliable, turn-key performance. But they don’t stop there: their embedded web server provides a uniquely simple control interface, allowing wireless operation from any laptop, tablet or smartphone.Their focus is on manufacturing femtosecond lasers for life-sciences applications. In parallel with these core products, they work with systems manufacturers to provide custom OEM femtosecond and picosecond lasers optimized for specific applications in engineering and materials processing. They can provide combinations of pulse repetition rate, energy and wavelength not available from any other manufacturers. | $1.7M / Seed / Aug 11, 2021 | |
ENOUGH
|
ENOUGH is a technology spin-out company from the University of Strathclyde established to develop and commercialise novel patented technology which transforms the production economics for the meat-free food product mycoprotein by integrating the production within existing bio-refinery operations producing bio-ethanol and animal feed (DDGS). Thisgives integrated fermentation production of Food, Fuel and Feed. | $8.1M / Series A / Apr 04, 2018 | |
|
ENOUGH
|
ENOUGH is a technology spin-out company from the University of Strathclyde established to develop and commercialise novel patented technology which transforms the production economics for the meat-free food product mycoprotein by integrating the production within existing bio-refinery operations producing bio-ethanol and animal feed (DDGS). Thisgives integrated fermentation production of Food, Fuel and Feed. | $604K / Seed / Jul 16, 2017 | |
Alfacyte
|
Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy. | $327K / Jan 04, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does EOS Technology Investment Syndicate invest in?
EOS Technology Investment Syndicate invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact EOS Technology Investment Syndicate?
Public channels for EOS Technology Investment Syndicate include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EOS Technology Investment Syndicate?
The team at EOS Technology Investment Syndicate includes Kevin Grainger (Chairman & Gatekeeper). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
